MaxCyte, Inc. (MXCT) shareholders
MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value
$1.10−0.03 (-2.65%)
Close on Nov 11, 2026Market cap $113.53MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
61.3%
63M of 103M shares
Institutional holders
123
27 new, 33 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 1 sales
Net sold $8.32K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Capricorn Fund Managers Ltd | 8,200,000 | 7.70% | 13G (passive) | Jan 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MXCT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Capricorn Fund Managers Ltd | 8,200,000 | 7.95% | $10.09M | – | 0.79% |
| Vitruvian Partners LLP | 5,043,356 | 4.89% | $6.20M | – | 3.09% |
| Vanguard Capital Management LLC | 4,031,284 | 3.91% | $4.96M | +49,468 | 0.00% |
| Morgan Stanley | 3,694,049 | 3.58% | $4.54M | +5,918 | 0.00% |
| Mudita Advisors LLP | 3,370,689 | 3.27% | $4.15M | – | 0.86% |
| BlackRock, Inc. | 3,060,960 | 2.97% | $3.76M | −5,737,513 | 0.00% |
| Brooklands Fund Management Ltd | 2,848,083 | 2.76% | $3.67M | +658,063 | 2.87% |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2,773,554 | 2.69% | $3.41M | – | 0.00% |
| Cadian Capital Management, LP | 2,201,166 | 2.13% | $2.71M | +478,224 | 0.20% |
| Peapod Lane Capital LLC | 2,125,752 | 2.06% | $2.61M | +793,559 | 1.76% |
| Renaissance Technologies LLC | 1,910,800 | 1.85% | $2.35M | −82,400 | 0.00% |
| Aqr Capital Management LLC | 1,882,776 | 1.82% | $2.32M | +661,594 | 0.00% |
| Jane Street Group, LLC | 1,563,003 | 1.51% | $1.92M | +1,542,434 | 0.00% |
| Two Sigma Investments, LP | 1,462,941 | 1.42% | $1.80M | +854,779 | 0.00% |
| Geode Capital Management, LLC | 1,326,914 | 1.29% | $1.63M | −1,035,758 | 0.00% |
| RBF Capital, LLC | 1,322,443 | 1.28% | $1.63M | New | 0.07% |
| Goldman Sachs Group Inc | 1,241,943 | 1.20% | $1.53M | +82,924 | 0.00% |
| Millennium Management LLC | 1,204,921 | 1.17% | $1.48M | +1,161,862 | 0.00% |
| Nano Cap New Millennium Growth Fund L P | 1,200,000 | 1.16% | $1.48M | +200,000 | 1.14% |
| Marshall Wace, Llp | 1,014,778 | 0.98% | $1.25M | +915,866 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 123 | 63M | 61.3% | 27 / 51 | 28 / 33 | 13M | 15M |
| Q1 2026 | 131 | 65M | 63.4% | 39 / 30 | 36 / 19 | 25M | 18M |
| Q4 2025 | 112 | 64M | 61.8% | 20 / 28 | 37 / 16 | 8M | 12M |
| Q3 2025 | 112 | 70M | 68.0% | 17 / 33 | 40 / 24 | 10M | 11M |
| Q2 2025 | 120 | 71M | 69.2% | 21 / 43 | 37 / 15 | 7M | 10M |
| Q1 2025 | 114 | 75M | 72.3% | 12 / 41 | 42 / 14 | 12M | 4M |
| Q4 2024 | 119 | 73M | 70.3% | 21 / 45 | 30 / 21 | 10M | 6M |
| Q3 2024 | 120 | 69M | 66.8% | 13 / 50 | 30 / 6 | 12M | 4M |
| Q2 2024 | 114 | 69M | 66.4% | 9 / 49 | 39 / 17 | 5M | 11M |
| Q1 2024 | 123 | 74M | 71.8% | 15 / 42 | 46 / 12 | 10M | 6M |
| Q4 2023 | 120 | 71M | 68.4% | 20 / 50 | 29 / 20 | 21M | 15M |
| Q3 2023 | 120 | 64M | 62.4% | 17 / 42 | 39 / 12 | 5M | 7M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
114 funds held MXCT in Q1 2026, 60% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MXCT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,742,125 | 2.66% | $3.37M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,161,395 | 1.13% | $1.43M | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 518,559 | 0.50% | $627.46K | 0.00% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 394,028 | 0.38% | $476.77K | 0.00% | May 31, 2026 |
| Inception Portfolio | 347,433 | 0.34% | $427.34K | 0.15% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 301,966 | 0.29% | $365.38K | 0.00% | May 31, 2026 |
| EQ/Morgan Stanley Small Cap Growth Portfolio | 211,975 | 0.21% | $260.73K | 0.05% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 199,501 | 0.19% | $241.40K | 0.00% | May 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 164,501 | 0.16% | $202.34K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 156,238 | 0.15% | $189.05K | 0.00% | May 31, 2026 |
| Multi-Manager Small Cap Equity Strategies Fund | 144,027 | 0.14% | $174.27K | 0.01% | May 31, 2026 |
| Schwab Total Stock Market Index Fund | 114,828 | 0.11% | $120.57K | 0.00% | Jul 31, 2026 |
| Large-Cap Growth Portfolio | 109,790 | 0.11% | $135.04K | 0.01% | Jun 30, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 109,491 | 0.11% | $134.67K | 0.00% | Jun 30, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 94,709 | 0.09% | $114.60K | 0.61% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Maher Masoud | President and CEO, Director | 475,000 | 0.46% | Mar 31, 2026 |
| Parmeet Ahuja | Chief Financial Officer | 187,500 | 0.18% | Apr 17, 2026 |
| Douglas J. Swirsky | CHIEF FINANCIAL OFFICER | 151,669 | 0.15% | Mar 19, 2026 |
| Ali Soleymannezhad | Chief Commercial Officer | 59,439 | 0.06% | Mar 20, 2025 |
| David I. Sandoval | GENERAL COUNSEL | 64,219 | 0.06% | Mar 20, 2025 |
| Rekha Hemrajani | Director | 70,314 | 0.07% | Jun 22, 2026 |
| Patrick J. Balthrop | Director | 80,998 | 0.08% | Jun 22, 2026 |
| John Joseph Johnston | Director | 201,581 | 0.20% | Jun 22, 2026 |
| Richard Douglas | Director | 260,998 | 0.25% | Jun 22, 2026 |
| Yasir B. Al-Wakeel | Director | 80,998 | 0.08% | Jun 22, 2026 |
| William W. Brooke | Director | 181,300 | 0.18% | Jun 22, 2026 |
| Stanley C. Erck | Director | 428,749 | 0.42% | Jun 22, 2026 |
| Cynthia Collins | Director | 111,310 | 0.11% | Jun 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard Douglas Director | Jun 17, 2026 | Award | +30,421 | – | – | 260,998 |
| William W. Brooke Director | Jun 17, 2026 | Award | +30,421 | – | – | 181,300 |
| Yasir B. Al-Wakeel Director | Jun 17, 2026 | Award | +30,421 | – | – | 80,998 |
| Rekha Hemrajani Director | Jun 17, 2026 | Award | +30,421 | – | – | 70,314 |
| Patrick J. Balthrop Director | Jun 17, 2026 | Award | +30,421 | – | – | 80,998 |
| Cynthia Collins Director | Jun 17, 2026 | Award | +30,421 | – | – | 111,310 |
| Stanley C. Erck Director | Jun 17, 2026 | Award | +30,421 | – | – | 428,749 |
| John Joseph Johnston Director | Jun 17, 2026 | Award | +30,421 | – | – | 201,581 |
| Parmeet Ahuja Chief Financial Officer | Apr 15, 2026 | Award | +187,500 | – | – | 187,500 |
| Maher Masoud President and CEO, Director | Mar 27, 2026 | Award | +300,000 | – | – | 475,000 |
| Douglas J. Swirsky CHIEF FINANCIAL OFFICER | Mar 17, 2026 | Sale | −10,142 | $0.82 | $8.32K | 151,669 |
| Stanley C. Erck Director | Aug 13, 2025 | Buy | +100,000 | $1.37 | $137.00K | 398,328 |
| Richard Douglas Director | Aug 13, 2025 | Buy | +80,000 | $1.39 | $111.20K | 230,577 |
| William W. Brooke Director | Aug 13, 2025 | Buy | +50,000 | $1.29 | $64.50K | 150,879 |
| Maher Masoud President and CEO, Director | Aug 13, 2025 | Buy | +75,000 | $1.37 | $102.75K | 175,000 |
| Douglas J. Swirsky CHIEF FINANCIAL OFFICER | Aug 13, 2025 | Buy | +50,000 | $1.29 | $64.50K | 161,811 |
| Rekha Hemrajani Director | Jun 25, 2025 | Sale(10b5-1 plan) | −10,684 | $2.09 | $22.33K | 39,893 |
| Rekha Hemrajani Director | Jun 18, 2025 | Award | +29,210 | – | – | 50,577 |
| Yasir B. Al-Wakeel Director | Jun 18, 2025 | Award | +29,210 | – | – | 50,577 |
| Patrick J. Balthrop Director | Jun 18, 2025 | Award | +29,210 | – | – | 50,577 |
| Richard Douglas Director | Jun 18, 2025 | Award | +29,210 | – | – | 150,577 |
| Cynthia Collins Director | Jun 18, 2025 | Award | +29,210 | – | – | 80,889 |
| William W. Brooke Director | Jun 18, 2025 | Award | +29,210 | – | – | 100,879 |
| John Joseph Johnston Director | Jun 18, 2025 | Award | +29,210 | – | – | 171,160 |
| Stanley C. Erck Director | Jun 18, 2025 | Award | +29,210 | – | – | 298,328 |
| David I. Sandoval GENERAL COUNSEL | Mar 18, 2025 | Sale | −353 | $3.18 | $1.12K | 64,219 |
| Ali Soleymannezhad Chief Commercial Officer | Mar 18, 2025 | Sale | −1,211 | $3.18 | $3.85K | 59,439 |
| Douglas J. Swirsky CHIEF FINANCIAL OFFICER | Mar 18, 2025 | Sale | −6,939 | $3.18 | $22.07K | 111,811 |
| Douglas J. Swirsky CHIEF FINANCIAL OFFICER | Mar 14, 2025 | Award | +37,500 | – | – | 118,750 |
| Ali Soleymannezhad Chief Commercial Officer | Mar 14, 2025 | Award | +34,625 | – | – | 60,650 |
| David I. Sandoval GENERAL COUNSEL | Mar 14, 2025 | Award | +23,125 | – | – | 64,572 |
| John Joseph Johnston Director | Jan 27, 2025 | Option exercise | +3,000 | $2.93 | $8.79K | 144,950 |
| John Joseph Johnston Director | Jan 27, 2025 | Sale(10b5-1 plan) | −3,000 | $4.65 | $13.95K | 141,950 |
| David I. Sandoval GENERAL COUNSEL | Jan 13, 2025 | Sale | −4,466 | $4.54 | $20.28K | 41,447 |
| John Joseph Johnston Director | Dec 26, 2024 | Sale(10b5-1 plan) | −3,000 | $4.01 | $12.03K | 141,950 |
| John Joseph Johnston Director | Dec 26, 2024 | Option exercise | +3,000 | $2.93 | $8.79K | 144,950 |
| John Joseph Johnston Director | Dec 9, 2024 | Option exercise | +891 | $2.93 | $2.61K | 142,841 |
| John Joseph Johnston Director | Dec 9, 2024 | Option exercise | +1,121 | $1.64 | $1.84K | 143,962 |
| John Joseph Johnston Director | Dec 9, 2024 | Option exercise | +483 | $2.93 | $1.42K | 144,445 |
| John Joseph Johnston Director | Dec 9, 2024 | Sale(10b5-1 plan) | −2,495 | $3.79 | $9.46K | 141,950 |
| John Joseph Johnston Director | Dec 6, 2024 | Sale(10b5-1 plan) | −505 | $3.70 | $1.87K | 141,950 |
| John Joseph Johnston Director | Dec 6, 2024 | Option exercise | +505 | $2.93 | $1.48K | 142,455 |
| Stanley C. Erck Director | Nov 1, 2024 | Sale(10b5-1 plan) | −47,689 | $3.72 | $177.40K | 269,118 |
| Stanley C. Erck Director | Nov 1, 2024 | Option exercise | +47,689 | $0.04 | $1.91K | 316,807 |
| John Joseph Johnston Director | Oct 28, 2024 | Option exercise | +3,000 | $2.93 | $8.79K | 144,950 |
| John Joseph Johnston Director | Oct 28, 2024 | Sale(10b5-1 plan) | −3,000 | $3.72 | $11.16K | 141,950 |
| Cynthia Collins Director | Oct 14, 2024 | Award | +51,679 | – | – | 51,679 |
| Stanley C. Erck Director | Oct 2, 2024 | Sale(10b5-1 plan) | −21,607 | $3.71 | $80.16K | 269,118 |
| Stanley C. Erck Director | Oct 2, 2024 | Option exercise | +21,607 | $0.04 | $864 | 290,725 |
| Stanley C. Erck Director | Oct 1, 2024 | Option exercise | +26,082 | $0.04 | $1.04K | 295,200 |
| Stanley C. Erck Director | Oct 1, 2024 | Sale(10b5-1 plan) | −26,082 | $3.78 | $98.59K | 269,118 |
| John Joseph Johnston Director | Sep 26, 2024 | Option exercise | +3,000 | $2.93 | $8.79K | 144,950 |
| John Joseph Johnston Director | Sep 26, 2024 | Sale(10b5-1 plan) | −3,000 | $3.82 | $11.46K | 141,950 |
| Ali Soleymannezhad Chief Commercial Officer | Sep 16, 2024 | Award | +10,400 | – | – | 26,025 |
| Stanley C. Erck Director | Sep 4, 2024 | Sale(10b5-1 plan) | −29,767 | $3.97 | $118.17K | 269,118 |
| Stanley C. Erck Director | Sep 4, 2024 | Option exercise | +29,767 | $0.04 | $1.19K | 298,885 |
| Stanley C. Erck Director | Sep 3, 2024 | Sale(10b5-1 plan) | −17,922 | $4.10 | $73.48K | 269,118 |
| Stanley C. Erck Director | Sep 3, 2024 | Option exercise | +17,922 | $0.04 | $717 | 287,040 |
| John Joseph Johnston Director | Aug 26, 2024 | Sale(10b5-1 plan) | −3,000 | $4.28 | $12.84K | 141,950 |
| John Joseph Johnston Director | Aug 26, 2024 | Option exercise | +3,000 | $2.93 | $8.79K | 144,950 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
1.67%
2M shares short
Days to cover
1.3
At 1M shares a day
Change since last report
-13.6%
From 2M shares
Short volume, 20 days
18.9%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of MaxCyte's stock actually held short. Settlement fails (shares not delivered on time) peaked at 14,626 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Rekha Hemrajani Director | Jun 25, 2025 | 10,684 | $22.38K | Jun 25, 2025 | Restricted Stock Units |
| John Joseph Johnston Affiliate | Dec 26, 2024 | 12,000 | $49.32K | Dec 26, 2024 | option exercise |
| John Joseph Johnston Affiliate | Sep 26, 2024 | 9,000 | $34.29K | Sep 26, 2024 | option exercise |
| Stanley C. Erck Officer | Sep 3, 2024 | 143,067 | $618.05K | Sep 3, 2024 | Option Exercise |
| John Joseph Johnston Affiliate | Jun 27, 2024 | 16,000 | $63.68K | Jun 27, 2024 | option exercise |
| Thomas M. Ross Officer | Jun 20, 2024 | 133,332 | $587.99K | Jun 20, 2024 | Option Exercise |
| John Joseph Johnston Affiliate | Feb 26, 2024 | 10,000 | $45.90K | Feb 26, 2024 | option exercise |
| Douglas Doerfler Officer | Nov 29, 2023 | 150,000 | $702.00K | Nov 29, 2023 | Option Exercise |
| John Joseph Johnston Affiliate | Nov 14, 2023 | 20,000 | $74.20K | Nov 14, 2023 | option exercise |
| Douglas Doerfler Officer | Jul 10, 2023 | 90,000 | $416.70K | Jul 10, 2023 | Option Exercise |
| John Joseph Johnston Affiliate | Jun 26, 2023 | 25,000 | $117.00K | Jun 26, 2023 | option exercise |
See a number that looks wrong?